GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a biotech company developing drugs to enhance the effectiveness of radiation therapy. Its stock price represents a venture bet on the success of its scientific developments in oncology.
Share prices of companies in the market segment - Cancer brain
Shuttle Pharmaceuticals develops drugs that enhance the effectiveness of radiation therapy in cancer treatment while simultaneously protecting healthy tissue. We've categorized it under "Brain Cancer." The chart below shows how investors value companies improving cancer treatment standards.
Broad Market Index - GURU.Markets
Shuttle Pharmaceuticals is an oncology company developing drugs to improve the effectiveness of radiation therapy. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SHPH - Daily change in the company's share price Shuttle Pharmaceuticals
For Shuttle Pharmaceuticals Holdings, Inc., an oncology company, daily volatility reflects sensitivity to clinical trial data. This metric is key to assessing the risks of its drugs that enhance the effectiveness of radiation therapy.
Daily change in the price of a set of shares in a market segment - Cancer brain
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective and less toxic. This is a highly specialized and risky niche in oncology. The chart below illustrates the volatility typical of the biotech sector, providing context for analyzing SHPH stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Shuttle Pharmaceuticals is a biotech company developing drugs to improve the effectiveness of radiation therapy for cancer. Its shares are driven by research news. This high volatility is a significant component of the overall "noise" and stock market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Shuttle Pharmaceuticals
Shuttle Pharmaceuticals' year-end performance is a story about its drug development to improve the effectiveness of radiation therapy. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach could fundamentally improve cancer treatment outcomes and reduce the side effects of radiation.
Annual dynamics of market capitalization of the market segment - Cancer brain
As an early-stage biotech, Shuttle is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs that improve radiation therapy. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shuttle Pharmaceuticals is a biotech company whose value is based on the hope of improving the results of radiation therapy. Its year-over-year performance relative to the market is not a reflection of business processes, but a speculative bet on success in clinical trials. The chart is a series of sharp movements driven by news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Shuttle Pharmaceuticals
Shuttle Pharma is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its drugs designed to enhance radiation therapy triggers investor reactions.
Monthly dynamics of market capitalization of the market segment - Cancer brain
Developing drugs that enhance the effectiveness of radiation therapy is a key challenge in oncology. The dynamics of this biotech sector, shown in the graph, reflects the risks and potential of such developments. Shuttle Pharmaceuticals is a company operating in this niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shuttle Pharma is an early-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on research data, paying little attention to overall market trends. The chart illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Shuttle Pharmaceuticals
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. Its weekly stock price performance is a direct response to clinical trial data. Success in this area could improve the standard of care for millions of cancer patients, which is driving investor interest.
Weekly dynamics of market capitalization of the market segment - Cancer brain
Shuttle Pharmaceuticals develops drugs that enhance the effectiveness of radiation therapy in cancer treatment. This is an important supportive therapy. The chart shows how investors view the company's progress in this niche and how its performance compares to other oncology biotechs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shuttle Pharmaceuticals develops radiation therapy drugs. This chart shows how investors view the company's progress in this niche and how its performance compares to other oncology biotechs and the market as a whole.
Market capitalization of the company, segment and market as a whole
SHPH - Market capitalization of the company Shuttle Pharmaceuticals
Shuttle Pharmaceuticals' market capitalization reflects investor bets on its drugs that enhance the effectiveness of radiation therapy. The chart shows the market's belief that its molecules can make cancer cells more vulnerable to radiation. Its low valuation reflects the scientific potential of its early-stage developments.
SHPH - Share of the company's market capitalization Shuttle Pharmaceuticals within the market segment - Cancer brain
Shuttle Pharmaceuticals develops drugs that make tumors more sensitive to radiation therapy. Its market share in the oncology sector is tiny, but it's solving an important problem. Its capitalization is a bet on its technology, which could improve the effectiveness of one of the leading cancer treatments.
Market capitalization of the market segment - Cancer brain
This chart shows the overall value of the entire oncology sector. For Shuttle Pharmaceuticals, which is focused on improving the effectiveness of radiation therapy, this line is a map of the future. The rising chart reflects investors' belief that new drugs will make traditional cancer treatments safer and more effective.
Market capitalization of all companies included in a broad market index - GURU.Markets
Shuttle Pharmaceuticals develops drugs that make radiation therapy more effective and less harmful. Its market capitalization is the valuation of its "assistant" for oncologists. This represents the market share of the company's business improving existing cancer treatments.
Book value capitalization of the company, segment and market as a whole
SHPH - Book value capitalization of the company Shuttle Pharmaceuticals
Shuttle Pharmaceuticals develops drugs to improve the effectiveness of radiation therapy for cancer. Its book value represents its financial resources for research. It consists of cash that allows it to conduct clinical trials. How has this research capital changed? The chart below shows.
SHPH - Share of the company's book capitalization Shuttle Pharmaceuticals within the market segment - Cancer brain
Shuttle Pharmaceuticals is an oncology company developing sensitizers for radiation therapy. Its research requires a resource base: laboratories for developing and testing its drug candidates. The chart shows the company's share of the physical R&D infrastructure in this segment.
Market segment balance sheet capitalization - Cancer brain
Shuttle Pharmaceuticals is an oncology company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Shuttle focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Shuttle Pharmaceuticals' assets are not drugs, but rather drug candidates being developed to make radiation therapy more effective and less toxic. The book value reflects capital invested in clinical trials of this supportive oncology therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is an oncology company developing drugs to enhance the effectiveness of radiation therapy. Its market value is determined by its research and its potential to improve standard cancer treatment.
Market to book capitalization ratio in a market segment - Cancer brain
Shuttle Pharmaceuticals is developing drugs that make cancer radiation therapy more effective. This chart shows how investors view this important technology and its potential to improve cancer treatment outcomes.
Market to book capitalization ratio for the market as a whole
Shuttle Pharmaceuticals develops drugs that enhance the effectiveness of radiation therapy. The company's market value reflects a bet that its technology will improve the standard of cancer treatment. This chart shows how investors value "assistive" technologies in oncology, which have the potential to have a huge market.
Debts of the company, segment and market as a whole
SHPH - Company debts Shuttle Pharmaceuticals
Shuttle Pharma, a company developing drugs to enhance the effectiveness of cancer radiation therapy, is in the clinical stage and is entirely dependent on external funding. This chart shows how the company is raising funds to test its scientific hypothesis, which could improve the current standard of care.
Market segment debts - Cancer brain
Shuttle Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs that make cancer radiation therapy more effective. This chart shows how the company is funding its research to improve standard cancer treatments, a complex but potentially highly significant goal.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Shuttle Pharmaceuticals
Shuttle Pharmaceuticals develops drugs that make tumors more sensitive to radiation therapy. Clinical trials in this niche area of oncology require significant investment. This chart shows how the company uses debt to finance its research and development efforts aimed at improving the effectiveness of cancer treatments.
Market segment debt to market segment book capitalization - Cancer brain
Shuttle Pharmaceuticals develops drugs that make radiation therapy for cancer more effective. This is an important supportive therapy. This chart shows how the company finances its clinical trials. It relates its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. This is an important niche in oncology, but like any pharmaceutical development, it requires significant investment. How reliant is the company on debt? This chart of total market debt provides context for assessing its financial strategy.
P/E of the company, segment and market as a whole
P/E - Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs that make tumors more sensitive to radiation therapy. This chart shows how investors view its approach to improving the effectiveness of cancer treatment.
P/E of the market segment - Cancer brain
Shuttle Pharmaceuticals develops radiosensitizers designed to enhance the effectiveness of radiation therapy in cancer treatment and reduce its side effects. This chart illustrates the average valuation in the oncology research sector, where investors evaluate the potential of technologies to improve standard treatments.
P/E of the market as a whole
Shuttle Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs that enhance the effectiveness of radiation therapy for cancer treatment. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether SHPH's valuation is based on faith in its unique approach to cancer treatment or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is developing drugs that make cancer tumors more sensitive to radiation therapy, increasing its effectiveness. This could become an important addition to standard treatment. This chart shows how much investors believe in this approach and the commercial potential of the company's oncology drugs.
%20P%2FE%20Shuttle%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Shuttle-Pharmaceuticals&v=1772513496844 "Chart of the company's future (projected) P/E Shuttle Pharmaceuticals")
Future (projected) P/E of the market segment - Cancer brain
Shuttle Pharmaceuticals develops radiosensitizers designed to improve the effectiveness of radiation therapy in cancer treatment. The chart reflects the sector's future profit expectations and helps understand how high investors' hopes are that Shuttle's technology will improve the standard of cancer treatment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-brain&v=1772513496857 "Future (projected) P/E graph of the market segment - Cancer brain")
Future (projected) P/E of the market as a whole
Shuttle Pharmaceuticals develops drugs that make cancer tumors more sensitive to radiation therapy, increasing its effectiveness. This is called adjuvant therapy. This biotech risk appetite chart reflects how willing investors are to invest in technologies that enhance existing treatments, rather than replace them.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513496984 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs that make cancer tumors more sensitive to radiation therapy. Its financial indicators reflect R&D expenditures. This chart shows investments in a technology that could improve the effectiveness of one of the leading cancer treatments.
Profit of companies in the market segment - Cancer brain
Shuttle Pharmaceuticals is a clinical-stage company focused on improving the results of cancer radiation therapy. Its drugs are designed to protect healthy tissue and enhance the effects of radiation on tumors. This chart shows the overall profitability of the brain cancer and other oncology treatment sector, where improving the effectiveness of existing treatments is critical.
Overall market profit
Shuttle Pharmaceuticals is developing drugs that enhance the effectiveness of radiation therapy in cancer treatment. The company is in clinical trials. Its future depends entirely on the success of these studies. The overall economic environment, as shown in this chart, does not impact the need to improve cancer treatment outcomes.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Shuttle Pharmaceuticals
Shuttle Pharmaceuticals develops drugs that make tumors more sensitive to radiation therapy, increasing its effectiveness. Future profits depend on the success of this technology in clinical trials. This chart reflects analysts' hopes that the company will be able to improve one of the leading cancer treatments.
%20profit%20of%20the%20company%20Shuttle%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Shuttle-Pharmaceuticals&v=1772513497201 "Graph of future (projected) profit of the company Shuttle Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Cancer brain
Shuttle Pharmaceuticals is developing radiosensitizers that make tumors more sensitive to radiation therapy. This could improve the effectiveness of cancer treatments and reduce side effects. This chart shows revenue projections for the brain cancer treatment sector, helping to assess the potential of Shuttle's technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-brain&v=1772513497218 "Graph of future (predicted) profits of companies in a market segment - Cancer brain")
Future (predicted) profit of the market as a whole
Shuttle Pharmaceuticals is developing drugs that make cancer radiation therapy more effective. Its future depends on the success of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513497234 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Shuttle Pharmaceuticals
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. There is no revenue at the clinical stage. This chart reflects investors' confidence in its scientific approach and the potential market for drugs that can improve standard cancer treatment.
P/S market segment - Cancer brain
Shuttle Pharmaceuticals is a clinical-stage company focused on improving the outcomes of cancer radiation therapy. Their drugs are designed to simultaneously enhance the effectiveness of tumor irradiation while protecting healthy tissue. This chart reflects the average revenue estimate for the sector, helping to assess the market's perception of the potential of this important innovation in oncology.
P/S of the market as a whole
Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company developing drugs that make cancer radiation therapy more effective. This chart highlights that the valuation of such companies is based on their ability to improve existing treatment standards, which could create significant value if successful.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs that make tumors more sensitive to radiation therapy. Its revenue valuation is crucial for the company, reflecting investors' hopes that its technology will significantly improve the effectiveness of standard cancer treatments and become an integral part of them.
%20P%2FS%20Shuttle%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Shuttle-Pharmaceuticals&v=1772513497299 "The graph of the company's future (projected) P/S Shuttle Pharmaceuticals")
Future (projected) P/S of the market segment - Cancer brain
Shuttle Pharmaceuticals develops drugs that make radiation therapy more effective in treating cancer. This chart compares the company's estimated future sales with expectations for the oncology sector. It shows how investors view the potential of its radiosensitizing agents to improve treatment standards and patient outcomes.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20brain&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-brain&v=1772513497314 "Future (projected) P/S market segment graph - Cancer brain")
Future (projected) P/S of the market as a whole
Shuttle Pharmaceuticals is developing radiosensitizers that make tumors more sensitive to radiation therapy, increasing its effectiveness. The company's future depends on the success of this technology in the clinic. This chart of overall market expectations reflects investor confidence that even improvements to existing cancer treatments can have significant commercial potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513497334 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Shuttle Pharmaceuticals
This chart shows the financial activity of Shuttle Pharmaceuticals, a clinical-stage company developing drugs to improve the effectiveness of cancer radiation therapy. There are no commercial sales revenues, and cash flows are related to R&D expenses.
Sales of companies in the market segment - Cancer brain
Shuttle Pharmaceuticals is a clinical-stage oncology company developing drugs that make radiation therapy more effective and less toxic. It currently has no sales revenue. Its future revenue depends on the success of its unique approach to improving the standard of cancer treatment.
Overall market sales
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. The company is working to improve the current standard of treatment. This general economics chart has nothing to do with the company, whose mission is to improve the chances of survival and quality of life for cancer patients.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company developing radiosensitizers that make tumors more susceptible to radiation therapy. Future revenues are dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its drugs to improve cancer treatment outcomes.
%20sales%20of%20the%20company%20Shuttle%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Shuttle-Pharmaceuticals&v=1772513497483 "Schedule of future (projected) sales of the company Shuttle Pharmaceuticals")
Future (projected) sales of companies in the market segment - Cancer brain
Shuttle Pharmaceuticals develops drugs that make radiation therapy more effective. This chart shows revenue forecasts for the entire oncology market. Is demand growing for adjuvant therapies that can improve the results of standard cancer treatments? This reflects general trends in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-brain&v=1772513497501 "Schedule of future (projected) sales of companies in the market segment - Cancer brain")
Future (projected) sales of the market as a whole
Shuttle Pharmaceuticals develops drugs that enhance the effectiveness of radiation therapy in cancer treatment. The company's success depends on the results of clinical trials and its ability to improve treatment standards. This schedule does not affect cancer patients' need for more effective and safer treatment, which is the primary driver of its business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513497507 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company focused on improving the results of cancer radiation therapy. This chart shows its financial trajectory. Profitability depends on the success of its radiosensitizer drugs, which are designed to enhance the effectiveness of tumor irradiation while protecting healthy tissue.
Market segment marginality - Cancer brain
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing drugs that make cancer radiation therapy more effective. This chart reflects its financial position, where profitability depends on success in clinical trials and the ability to improve standard cancer treatments.
Market marginality as a whole
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. The company aims to improve the current standard of care. This overall profitability chart reflects the investment climate in oncology and the market's willingness to fund technologies that complement, rather than replace, traditional methods.
Employees in the company, segment and market as a whole
Number of employees in the company Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage company developing drugs that make cancer tumors more sensitive to radiation therapy. Its very small staff consists of key scientists and managers. This graph shows the compact team working to advance their technology through clinical trials.
Share of the company's employees Shuttle Pharmaceuticals within the market segment - Cancer brain
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. Its activities are focused on clinical trials and require a team of oncologists and radiation biologists. This chart shows the company's market share, reflecting the scale of its research program and its focus on the niche field of radiation oncology.
Number of employees in the market segment - Cancer brain
Shuttle Pharmaceuticals is developing radiosensitizers that enhance the effectiveness of radiation therapy in cancer treatment. The chart shows employment in the brain oncology sector. Shuttle's technology could achieve better treatment outcomes with lower radiation doses, reducing side effects for patients.
Number of employees in the market as a whole
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. Its growth depends on success in clinical trials. Given the overall dynamics in this chart, Shuttle exemplifies a highly specialized biotech company where every employee contributes to improving existing treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Shuttle Pharmaceuticals (SHPH)
Shuttle Pharmaceuticals is a biotech company developing radiosensitizers that make tumors more vulnerable to radiation therapy. This is niche R&D. This chart shows how the market values their IP. It reflects the market value per scientist, which is a bet on their technology to improve radiation therapy.
%20of%20the%20company%20Shuttle%20Pharmaceuticals%20(SHPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Shuttle-Pharmaceuticals-SHPH&v=1772513497736 "Chart of market capitalization per employee (in thousands of dollars) of the company Shuttle Pharmaceuticals (SHPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer brain
Shuttle Pharmaceuticals (SHPH) develops drugs that make radiation therapy more effective. In this highly specialized field of oncology, this chart is a testament to their scientific approach. Their high capitalization per employee suggests that their sensitizer drugs have the potential to significantly improve treatment outcomes for millions of cancer patients.
%20by%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-brain&v=1772513497751 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer brain")
Market capitalization per employee (in thousands of dollars) for the overall market
Shuttle Pharmaceuticals develops drugs that make cancer radiation therapy more effective. Its pricing is based on the potential of this adjuvant therapy. The chart shows a high valuation per employee, as its product could improve the standard of care for millions of cancer patients, creating a huge potential market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513497761 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Shuttle Pharmaceuticals (SHPH)
Shuttle Pharmaceuticals is a clinical-stage biotech company developing drugs that make cancer radiation therapy more effective. This chart shows the net loss per employee, reflecting the fact that every scientist at the company represents an R&D investment, funding clinical trials.
%20Chart%20Shuttle%20Pharmaceuticals%20(SHPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Shuttle-Pharmaceuticals-SHPH&v=1772513497772 "Company Profit Per Employee (in thousands of dollars) Chart Shuttle Pharmaceuticals (SHPH)")
Profit per employee (in thousands of dollars) in the market segment - Cancer brain
Shuttle Pharmaceuticals Holdings, Inc. is a biopharmaceutical company developing drugs to improve the effectiveness of cancer radiation therapy. In this important oncology niche, efficiency per employee reflects the potential of their developments. The graph shows the financial return per team, which is an indicator of progress towards improving treatment standards.
%20in%20the%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-brain&v=1772513497791 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer brain")
Profit per employee (in thousands of dollars) for the market as a whole
Shuttle Pharmaceuticals is a biotech company focused on improving radiation therapy. They develop drugs that make tumors more sensitive to radiation. This is an R&D business. This chart, showing average market efficiency, helps to understand the contrast with biotech, where a team of scientists burns through capital.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513497822 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Shuttle Pharmaceuticals (SHPH)
Shuttle Pharmaceuticals is developing drugs that enhance the effectiveness of radiation therapy in cancer treatment. At the clinical stage, this figure is negligible. It reflects future potential: a successful drug could become a standard of care and generate huge revenues, leading to explosive growth in this area.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Shuttle-Pharmaceuticals-SHPH&v=1772513497843 "Sales chart per company employee Shuttle Pharmaceuticals (SHPH)")
Sales per employee in the market segment - Cancer brain
Shuttle Pharmaceuticals (SHPH) is a clinical-stage biotech developing drugs (sensitizers) that make tumors more susceptible to radiation therapy. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of Shuttle's R&D staffing efficiency.
Sales per employee for the market as a whole
Shuttle Pharmaceuticals (SHPH) is a biotech company developing sensitizers that make cancer radiation therapy more effective. Currently, their business is focused on R&D. This chart reflects their clinical stage: the company invests in research and has no revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Shuttle Pharmaceuticals (SHPH)
Shuttle Pharma (SHPH) is a biotech company developing drugs that aim to enhance the effectiveness of radiation therapy in cancer treatment. This chart shows the number of short positions. The bears are betting that clinical trials will fail to demonstrate this "enhanced" effect.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Shuttle-Pharmaceuticals-SHPH&v=1772513497908 "Short Shares Chart for the Company Shuttle Pharmaceuticals (SHPH)")
Shares shorted by market segment - Cancer brain
Shuttle Pharmaceuticals (SHPH) is an oncology company developing drugs (radiosensitizers) that are expected to improve the effectiveness of radiation therapy. This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism regarding the risks of clinical trials.
Shares shorted by the overall market
Shuttle Pharmaceuticals is a biotech company developing drugs to enhance radiation therapy. It's an R&D project. This chart reflects the overall market pessimism. When investors are fearful, they're unwilling to fund "long-term science." They see a "cash burn" and fear they'll run out of money before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Shuttle Pharmaceuticals (SHPH)
Shuttle Pharmaceuticals is developing sensitizers that make radiation therapy for cancer (especially brain cancer) more effective. This graph is the "pulse" of their R&D. It "warms" with positive clinical trial data showing improved patient outcomes, reflecting speculative interest.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Shuttle-Pharmaceuticals-SHPH&v=1772513497949 "RSI 14 indicator chart for the company's stock Shuttle Pharmaceuticals (SHPH)")
RSI 14 Market Segment - Cancer brain
Shuttle Pharma (SHPH) is a biotech company working on "radiosensitizers." These are drugs that make brain tumors more sensitive to radiation therapy. This chart measures the pulse of the Oncology/Brain Cancer sector. It helps distinguish SHPH's performance from general "overheating" or "overselling" in the biotech sector.
RSI 14 for the overall market
For Shuttle Pharma (SHPH), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SHPH (Shuttle Pharmaceuticals)
Shuttle Pharma is a biotech company developing "sensitizer" drugs that make radiation therapy more effective in treating cancer (e.g., brain tumors). This chart shows the speculative average 12-month price target from analysts based on their assessment of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SHPH-Shuttle-Pharmaceuticals&v=1772513497973 "A chart showing analyst consensus forecasts for the expected stock price. SHPH (Shuttle Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price SHPH (Shuttle Pharmaceuticals)
Shuttle Pharma is an oncology company developing "radiosensitizers"—drugs that make brain tumors more vulnerable to radiation therapy. This chart shows how the current stock price differs from the "fair" value predicted by analysts. It reflects their faith in this R&D approach to "amplifying" therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SHPH-Shuttle-Pharmaceuticals&v=1772513497984 "A chart showing the difference between the consensus forecast and the actual stock price. SHPH (Shuttle Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Cancer brain
Shuttle Pharma is an R&D biotech company developing "radiosensitizers"—drugs that make brain tumors more vulnerable to radiation therapy. This chart reflects analysts' overall expectations for the entire brain cancer sector, demonstrating whether experts believe a breakthrough in the treatment of this complex disease is possible.
Analysts' consensus forecast for the overall market share price
Shuttle Pharmaceuticals is a biotech company specializing in developing drugs ("sensitizers") that make radiation therapy for cancer (including brain cancer) more effective. This chart shows the overall "risk appetite" in the market. For SHPH, a clinical-stage company, overall market optimism (the rising chart) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Shuttle Pharmaceuticals
Shuttle Pharma is a shield for radiation therapy. It's an R&D company developing radiosensitizers—drugs that (they claim) enhance the effects of radiation inside a tumor (brain cancer) and protect healthy tissue. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Cancer brain
Shuttle Pharmaceuticals is a biotech company focused not on directly treating cancer, but on improving the effectiveness of radiation therapy. Their drugs are designed to make radiation more lethal to tumors. This chart compares their composite index to the sector, showing how this important ancillary strategy compares to other biotechs.
The AKIM Index for the overall market
Shuttle Pharmaceuticals is a company developing treatments to improve the results of cancer radiation therapy (radiosensitizers). This chart, which reflects the market average, provides a macro backdrop. It helps assess how SHPH, which complements standard cancer treatments, compares to overall economic trends.
